Quantcast
Home > Quotes > MIRM

Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Quote & Summary Data

MIRM 
$13.05
*  
0.40
2.97%
Get MIRM Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading MIRM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 13.87 / $ 12.80
Share Volume
46,345
50 Day Avg. Daily Volume
N/A
Previous Close
$ 13.45
52 Week High / Low
$ 15.4999 / $ 12.05
Market Cap
300,355,785
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
46,345
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $13.05 is 8.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.87 $ 15.4999
 Low: $ 12.80 $ 12.05

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. We focus on diseases for which the unmet medical need is high and the biology for treatment is clear. Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of orphan liver diseases. We are initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. Based on improvements in pruritus, or itching, and other disease markers observed in Phase 2 clinical trials, we commenced enrollment in the Phase 3 MARCH clinical trial in PFIC in the second quarter of 2019 and are planning to initiate a Phase 3 clinical trial in ALGS in the first half of 2020.  ... More ...  



Risk Grade

Where does MIRM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.40
Open Date:
Aug. 16, 2019
Close Price:
$ 13.05
Close Date:
Aug. 16, 2019


Consensus Recommendation

Analyst Info